Sign Out
May cause a drug-induced lupus-like syndrome including glomerulonephritis, especially in patients receiving higher doses.
Postural hypotension may occur.
Use with caution in patients with cerebral vascular accidents and suspected coronary artery disease (CAD); myocardial stimulation produced by hydralazine can cause angina attacks and electrocardiogram (ECG) changes of myocardial ischemia; has been implicated in the production of myocardial infarction.
Use with caution in patients with mitral valvular disease; may increased pulmonary artery pressure in these patients.
Use with caution in patients with advanced renal impairment; dosage adjustment.
Hydralazine has been associated with peripheral neuritis (eg, paresthesia, numbness, tingling), possibly due to an antipyridoxine effect. Pyridoxine therapy should be initiated with onset of such symptoms.
Blood dyscrasias (eg, reduction in haemoglobin and red blood cell count, leucopenia, agranulocytosis, purpura) may occur, discontinue therapy if these hematologic effects occur.
